Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.

Q3 Pharmacology, Toxicology and Pharmaceutics

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2025-07-21 eCollection Date: 2025-07-01 DOI:10.1515/jbcpp-2025-0113

Saurav Misra, Ravi Kant Narayan, Manmeet Kaur

{"title":"Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.","authors":"Saurav Misra, Ravi Kant Narayan, Manmeet Kaur","doi":"10.1515/jbcpp-2025-0113","DOIUrl":null,"url":null,"abstract":"Introduction: Obesity is a major public health issue linked to various health complications. Retatrutide, a triple agonist peptide targeting the glucagon receptor, GIP receptor, and GLP-1 receptor, shows promise in addressing this need.Content: This systematic review assessed the safety and efficacy of retatrutide for obesity treatment using available clinical trial data. We conducted a comprehensive search of databases, including PubMed, Cochrane and ClinicalTrials.gov, from their inception until March 15, 2025 following PRISMA guidelines.Summary: Three articles were included in this systematic review, screening a total of 1,082 patients, with 691 randomly assigned to groups. The average age of participants was 54.26 ± 9.9 years, consisting of 335 men (48 %) and 356 women (52 %). Retatrutide was administered to 510 participants, while 130 received a placebo. The 12 mg dosage of retatrutide showed the most significant reductions in body weight, body mass index, and waist circumference. It also led to a higher percentage of patients achieving weight losses of ≥5 , 10, 15, and 20 %. Gastrointestinal adverse effects were the most commonly reported.Outlook: Weekly subcutaneous injections of retatrutide in obese patients resulted in significant weight loss and metabolic improvements compared to a placebo.","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"36 4","pages":"263-274"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Basic and Clinical Physiology and Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/jbcpp-2025-0113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Obesity is a major public health issue linked to various health complications. Retatrutide, a triple agonist peptide targeting the glucagon receptor, GIP receptor, and GLP-1 receptor, shows promise in addressing this need.

Content: This systematic review assessed the safety and efficacy of retatrutide for obesity treatment using available clinical trial data. We conducted a comprehensive search of databases, including PubMed, Cochrane and ClinicalTrials.gov, from their inception until March 15, 2025 following PRISMA guidelines.

Summary: Three articles were included in this systematic review, screening a total of 1,082 patients, with 691 randomly assigned to groups. The average age of participants was 54.26 ± 9.9 years, consisting of 335 men (48 %) and 356 women (52 %). Retatrutide was administered to 510 participants, while 130 received a placebo. The 12 mg dosage of retatrutide showed the most significant reductions in body weight, body mass index, and waist circumference. It also led to a higher percentage of patients achieving weight losses of ≥5 , 10, 15, and 20 %. Gastrointestinal adverse effects were the most commonly reported.

Outlook: Weekly subcutaneous injections of retatrutide in obese patients resulted in significant weight loss and metabolic improvements compared to a placebo.

查看原文本刊更多论文

利特鲁肽治疗肥胖的有效性和安全性：临床试验的系统回顾。

肥胖是一个主要的公共卫生问题，与各种健康并发症有关。利特鲁肽是一种靶向胰高血糖素受体、GIP受体和GLP-1受体的三重激动剂肽，有望解决这一需求。内容：本系统综述利用现有的临床试验数据评估了利特鲁肽治疗肥胖的安全性和有效性。我们根据PRISMA指南，对PubMed、Cochrane和ClinicalTrials.gov等数据库进行了全面的检索，从它们成立到2025年3月15日。摘要：本系统综述纳入了3篇文章，共筛选了1082例患者，其中691例随机分组。参与者的平均年龄为54.26±9.9岁，其中男性335人（48% %），女性356人（52% %）。510名受试者服用利特鲁肽，130名受试者服用安慰剂。12 mg剂量的利特鲁肽对体重、体重指数和腰围的降低最为显著。它还导致患者体重减轻的百分比更高，≥5% ，10%，15%和20% %。胃肠道不良反应是最常见的报道。展望：与安慰剂相比，肥胖患者每周皮下注射利特鲁肽可显著减轻体重和改善代谢。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Basic and Clinical Physiology and Pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.90

自引率

0.00%

发文量

期刊介绍： The Journal of Basic and Clinical Physiology and Pharmacology (JBCPP) is a peer-reviewed bi-monthly published journal in experimental medicine. JBCPP publishes novel research in the physiological and pharmacological sciences, including brain research; cardiovascular-pulmonary interactions; exercise; thermal control; haematology; immune response; inflammation; metabolism; oxidative stress; and phytotherapy. As the borders between physiology, pharmacology and biochemistry become increasingly blurred, we also welcome papers using cutting-edge techniques in cellular and/or molecular biology to link descriptive or behavioral studies with cellular and molecular mechanisms underlying the integrative processes. Topics: Behavior and Neuroprotection, Reproduction, Genotoxicity and Cytotoxicity, Vascular Conditions, Cardiovascular Function, Cardiovascular-Pulmonary Interactions, Oxidative Stress, Metabolism, Immune Response, Hematological Profile, Inflammation, Infection, Phytotherapy.